11.3 PBMs & ADRs
Key Takeaways
- Pharmacy Benefit Managers (PBMs) are third-party administrators of prescription drug programs for payers; the three largest U.S. PBMs are CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth)
- PBMs manage formularies, negotiate manufacturer rebates, reimburse pharmacies, administer pharmacy networks, and process claims adjudication in real time at the point of sale
- Spread pricing is the difference between what a PBM charges the payer and what it reimburses the pharmacy — a known industry issue under regulatory scrutiny
- An authorized distributor of record (ADR) is a distributor with which a manufacturer has an ongoing written relationship to distribute its products; buying outside the ADR network is a counterfeit and diversion risk
- Authorized trading-partner status ties directly to DSCSA, which requires trading partners to be authorized to increase supply chain security
Two topics round out Domain 3: the entities that pay for drugs (Pharmacy Benefit Managers) and the authorized-channel rules that keep drugs legitimate (authorized drug distribution and authorized trading partners). Both appear on the exam because they define where money flows and where product is allowed to flow.
Pharmacy Benefit Managers (PBMs)
A Pharmacy Benefit Manager (PBM) is a third-party administrator of prescription drug programs for payers — health insurers, employers, and government programs. The PBM does not insure the patient; it administers the drug benefit on behalf of the plan that does.
The Three Largest PBMs
The U.S. PBM market is highly concentrated. The three largest PBMs are:
- CVS Caremark (CVS Health)
- Express Scripts (Cigna)
- OptumRx (UnitedHealth Group)
These three together administer drug benefits for a very large share of insured Americans. On the exam, recognize all three as PBMs and know that each is owned by a larger healthcare company (CVS Health, Cigna, UnitedHealth respectively).
Core PBM Functions
| Function | What the PBM Does |
|---|---|
| Formulary management | Decides which drugs are covered, at what tier (preferred brand, non-preferred, generic), and what the patient copay is |
| Manufacturer rebate negotiation | Negotiates retrospective rebates from manufacturers in exchange for formulary placement (preferred status) |
| Pharmacy reimbursement | Sets the amount the pharmacy is paid for a prescription, typically based on a benchmark (MAC, NADAC, AWP minus a %) plus a dispensing fee |
| Pharmacy network administration | Defines which pharmacies a patient can use (in-network vs out-of-network); may include narrow or preferred networks |
| Claims adjudication | Processes the prescription claim electronically, in real time, at the point of sale |
Claims Adjudication at the Point of Sale
Claims adjudication is the real-time electronic processing of a prescription claim at the pharmacy counter. When the pharmacy submits a claim, the PBM's system checks in seconds:
- Is the patient eligible (covered by this plan)?
- Is the drug on the formulary (covered)?
- Are there coverage rules (prior authorization, quantity limits, step therapy)?
- What is the patient's cost share (copay or coinsurance)?
- What will the pharmacy be reimbursed?
The claim is adjudicated and the pharmacy gets a real-time response: paid, rejected, or reversed. This is the electronic plumbing that makes insurance work at the pharmacy counter.
Spread Pricing
Spread pricing is the difference between what a PBM charges the payer for a drug and what the PBM reimburses the pharmacy for that same drug. If the PBM charges the plan $100 and pays the pharmacy $90, the PBM keeps the $10 spread.
Spread pricing is a known industry issue under regulatory scrutiny. Critics argue it is opaque — the payer cannot see how much of its spend reaches the pharmacy versus the PBM. Some states and payers have moved toward pass-through pricing, where the PBM passes through the full reimbursement to the pharmacy and charges a transparent administrative fee instead. For the exam, define spread pricing as the difference between the price charged to the payer and the price paid to the pharmacy, and recognize it as a contested practice. The diagram below shows the full PBM claim and money flow.
The PBM's Dual Negotiation Role
A PBM negotiates with two sides at once:
- Upstream with manufacturers — for rebates tied to formulary placement (preferred status) and market share.
- Downstream with pharmacies — for reimbursement rates and network participation terms.
This dual role is why PBMs are sometimes described as sitting between the money. Whether rebates negotiated upstream are fully passed through to the payer or patient is a central transparency question in the industry.
Authorized Drug Distribution & Authorized Trading Partners
The second half of this section addresses supply chain security: making sure product only flows through authorized channels.
Authorized Drug Distributors / Authorized Distribution Networks
Manufacturers may limit distribution of a product to specific, authorized wholesale distributors rather than allowing any wholesaler to sell it. This is called an authorized distribution network (or authorized drug distribution). The purpose is to combat counterfeits and diversion:
- Counterfeits — fake or adulterated product introduced into the supply chain.
- Diversion — legitimate product sold through unauthorized channels (e.g., imported back into the U.S., stolen product resold).
Pharmacies should buy only from authorized distributors (authorized trading partners). Buying from an unverified secondary wholesaler — even at a steep discount — is a known counterfeit and diversion risk. On the exam, a "too-good-to-be-true" price from an unknown source signals an unauthorized channel.
Authorized Trading Partners and DSCSA
The concept ties directly to the Drug Supply Chain Security Act (DSCSA), covered in Chapter 3. Under DSCSA, trading partners in the supply chain — manufacturers, wholesale distributors, repackagers, and dispensers (pharmacies) — must be authorized trading partners. Being an authorized trading partner means:
- The entity is appropriately licensed with state and federal authorities.
- The entity is recognized by the manufacturer or upstream trading partner as authorized to handle the product.
- The product flow is traceable through T3 data (transaction information/history/statement).
Authorized distribution is one of the primary tools DSCSA uses to keep illegitimate product out of the legitimate supply chain. A pharmacy that buys only from authorized trading partners satisfies a core DSCSA security expectation.
"ADR" in the Supply-Chain Sense: Authorized Distributor of Record
In supply-chain usage, ADR stands for authorized distributor of record — a distributor with which a manufacturer has established an ongoing written relationship to distribute that manufacturer's products. The term comes from the Prescription Drug Marketing Act regulations (21 CFR 203.3) and carries into DSCSA-era practice: a manufacturer publishes or confirms its list of ADRs, and product moving through that list is presumptively legitimate.
Why it matters operationally:
- A wholesaler that is not an ADR for a given brand may still be a licensed wholesale distributor — but it obtained that brand somewhere other than the manufacturer, which is the definition of a secondary or grey-market source.
- "Authorized distributor of record" and "authorized trading partner" are not synonyms. Authorized trading partner is a DSCSA licensure status (registered manufacturer/repackager, licensed wholesaler/3PL/dispenser). ADR is a commercial relationship with one manufacturer. An entity can be an authorized trading partner and still not be an ADR for the product it is offering you.
- When an unfamiliar distributor offers a brand product, the two questions to ask are therefore separate: Are you an authorized trading partner? and Are you an authorized distributor of record for this product?
Be aware that outside the supply chain, ADR most often abbreviates adverse drug reaction — a clinical concept with no bearing on distribution. Read the abbreviation in context.
Specialty Drugs and Limited Distribution
Some specialty drugs — especially ultra-cold or limited-distribution drugs (LDDs) — are distributed only through a specialty pharmacy or a limited distribution network. This is a narrower form of authorized distribution: the manufacturer restricts which pharmacies may receive and dispense the product. Reasons include:
- Handling requirements (ultra-cold chain, e.g., −80 °C)
- Patient support programs (REMS, adherence, education)
- Data collection on real-world outcomes
Limited distribution is not the same as authorized distribution in general, but the underlying principle — restricting the channel for safety and control — is the same.
Exam Tying Points
- PBM = third-party administrator; formulary + rebates + reimbursement + networks + claims adjudication; CVS Caremark / Express Scripts / OptumRx.
- Spread pricing = charge to payer minus pay to pharmacy; contested; transparency issue.
- Authorized distribution = manufacturer limits product to specific authorized wholesalers to fight counterfeits/diversion.
- Authorized trading partner = DSCSA concept; entities must be licensed and authorized; pharmacies buy only from authorized sources.
- ADR = authorized distributor of record — a distributor with an ongoing written distribution relationship with the manufacturer (not adverse drug reaction, in this context).
A common scenario question: a pharmacy is offered a product at half the wholesaler's price from an unfamiliar distributor. The correct response is to decline and buy only from authorized trading partners — the offer signals a counterfeit/diversion risk that DSCSA is designed to prevent.
Which of the following is NOT one of the three largest U.S. Pharmacy Benefit Managers?
When a pharmacy submits a prescription claim, the PBM's system checks eligibility, formulary status, coverage rules, and cost share, then returns a paid or rejected response in seconds. What is this process called?
A PBM charges a health plan $102 for a drug and reimburses the pharmacy $94 for dispensing it. The $8 difference is best described as:
A pharmacy receives an offer from an unfamiliar distributor to supply a brand-name drug at roughly half the normal wholesaler price. Under DSCSA and authorized distribution principles, what is the appropriate response?
You've completed this section
Continue exploring other exams